Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy-Reference-Cited by-同舟云学术

Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy

Published:2016-08 Issue:4 Volume:39 Page:355-362
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Lee Victor H.F.,Chan Wendy W.L.,Lee Elaine Y.P.,Choy Tim-Shing,Ho Patty P.Y.,Leung Dennis K.C.,Lam Ka-On,Kwong Dora L.W.,Leung To-Wai,Khong Pek-Lan

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference33 articles.

1. Practice guidelines for non-small cell lung cancer;Cameron;Cancer J,1996

2. On behalf of the meta-analysis of cisplatin/carboplatin based concomitant chemotherapy in non-small cell lung cancer (MAC3-LC) group: concomitant radiochemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients;Auperin;Ann Oncol,2006

3. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non–small-cell lung cancer;Auperin;J Clin Oncol,2010

4. Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume;Basaki;Int J Radiat Oncol Biol Phys,2006

5. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy;Dehing-Oberije;Int J Radiat Oncol Biol Phys,2008

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Virtual clinical trials: A tool for predicting patients who may benefit from treatment beyond progression with pembrolizumab in non‐small cell lung cancer;CPT: Pharmacometrics & Systems Pharmacology;2022-12-22

2. Identification of non-small cell lung cancer (NSCLC) patients who benefit from treatment beyond progression with pembrolizumab from individual lesion response dynamics;2022-05-10

3. Can we define any marker associated with brain failure in patients with locally advanced non-small cell lung cancer?;Cancer/Radiothérapie;2021-06

4. Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review);Translational Lung Cancer Research;2021-04

5. Prognostic factors for overall survival of stage III non-small cell lung cancer patients on computed tomography: A systematic review and meta-analysis;Radiotherapy and Oncology;2020-10